Clinical trial
GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis…
NCT00089986 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00089986 |
|---|---|
| Title | GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults |
| Official title | A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sepsis |
| Intervention type | Drug, Other |
| Interventions | Intravenous GR270773- Phospholipid Emulsion, Placebo |
| Enrollment | 1,415 |
| Start date | Sep 1, 2004 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 15, 2007 |
| First posted | Aug 23, 2004 |
| Last update posted | Aug 21, 2017 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Estonia, Finland, France, Germany and 22 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: